Portage Biotech's (PRTG) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Portage Biotech (NASDAQ:PRTG – Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $11.00 target price on the stock. Separately, HC Wainwright lowered their target price on shares of Portage Biotech from $21.00 to $9.00 and set a buy […]

Related Keywords

,Millennium Management ,Portage Biotech Company Profile ,Cantor Fitzgerald ,Dimensional Fund Advisors ,Portage Biotech Inc ,Renaissance Technologies ,Goldman Sachs Group Inc ,Ieq Capital ,Portage Biotech ,Free Report ,Get Free Report ,Sachs Group ,Fund Advisors ,Biotech Inc ,Portage Biotech Daily ,Nasdaq Prtg ,Prtg ,Medical ,Reiterated Rating ,